CİPROPOL 2 MG/ML SOLUTION FOR I.V. INFUSION

CİPROPOL 2 MG/ML SOLUTION FOR I.V. INFUSION
Product Description

In the presence of acute bacterial sinusitis, uncomplicated urinary infection and alternative treatment options, it should not be used due to the risk of serious side effects. In these indications, it can only be used with the approval of an infectious diseases specialist if it is proven with an antibiogram and other alternative treatments cannot be applied. Adults • Complicated and uncomplicated infections induced by pathogens sensitive to ciprofloxacin • Respiratory tract infections: It is indicated in treatment of pneumonia induced by Klebsiella, Enterobacter spp, Proteus spp, E. coli, Pseudomonas aeruginosa, Haemophilus spp, Moraxella catarrhalis, Legionella ve Staphylococcus. It is especially indicated in middle ear infections (otitis media) and paranasal sinus infections (sinusitis) induced by gram negative organism or staphylococcus including Pseudomonas aeruginosa. • Eye infections (Treatment and prophylaxis of bacterial endophthalmitis) • Kidney and / or urinary tract infections • Infections of genital organs including adnexitis, prostatitis • Infections such as peritonitis, gastrointestinal tract, biliary tract infections • Skin and soft tissue infections • Bone and joint infections • Septicemia • Infections in patients with weakened immune system (for example, neutropenic patients or treated with immunosuppressive) or as prophylactic where there is a high risk of infection • Selective intestinal decontamination of patients with suppressed immune system Updated official directives related to suitable uses of antibacterial agents should be taken into consideration. 

Polifarma Ilac

  • TR
  • 2015
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
Pharmaceutical company
Primary activities
Animal Health
Finished Formulation products Distributor/Buyer
Laboratory, Analytical, Biotechnology Equipment
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
Transport/Logistics/Distribution
Specifications
  • CAS Registry Number
    26.05.2015 - 2015/46
  • Supplied from
    Türkiye

Polifarma Ilac

  • TR
  • 2015
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
Pharmaceutical company
Primary activities
Animal Health
Finished Formulation products Distributor/Buyer
Laboratory, Analytical, Biotechnology Equipment
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
Transport/Logistics/Distribution

More Products from Polifarma Ilac (54)

Polifarma Ilac resources (1)